Methamphetamine causes microglial activation in the brains of human abusers

Journal of Neuroscience

Volumn 28, Issue 22, 2008, Pages 5756-5761

  Sekine, Yoshimoto ^a,b   Ouchi, Yasuomi ^a,b   Sugihara, Genichi ^c   Takei, Nori ^c   Yoshikawa, Etsuji ^d   Nakamura, Kazuhiko ^b   Iwata, Yasuhide ^b   Tsuchiya, Kenji J ^c   Suda, Shiro ^b   Suzuki, Katsuaki ^b   Kawai, Masayoshi ^b   Takebayashi, Kiyokazu ^b   Yamamoto, Shigeyuki ^c   Matsuzaki, Hideo ^c   Ueki, Takatoshi ^b   Mori, Norio ^b,c   Gold, Mark S ^e   Cadet, Jean Lud ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Molecular Research Center for Children's Mental Development   (Japan)

^d Central Research Laboratory   (Japan)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Addiction; Human; Methamphetamine; Microglia; Neurotoxicity; Positron emission tomography

Indexed keywords

METHAMPHETAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; TRACER; ANTINEOPLASTIC AGENT; CARBON; CENTRAL STIMULANT AGENT; ISOQUINOLINE DERIVATIVE;

ADULT; ARTICLE; BRAIN REGION; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; HUMAN; MICROGLIA; NEUROPATHOLOGY; NEUROTOXICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; BRAIN; BRAIN MAPPING; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROTEIN BINDING; SCINTISCANNING;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN MAPPING; CARBON ISOTOPES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; ISOQUINOLINES; MAGNETIC RESONANCE IMAGING; MALE; METHAMPHETAMINE; MICROGLIA; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING;

EID: 45949092844     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1179-08.2008     Document Type: Article

References (48)

1. Al-Dirbashi OY, Kuroda N, Wada M, Takahashi M, Nakashima K (2000) Quantification of methamphetamine, amphetamine and enantiomers by semi-micro column HPLC with fluorescence detection; applications on abusers' single hair analyses. Biomed Chromatogr 14:293-300.
2. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, Ed 4. Washington, D.C.: American Psychiatric.
3. Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S (2000) History of the methamphetamine problem. J Psychoactive Drugs 32:137-141.
4. Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, Ogawa N (2003) Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett 352:13-16.
5. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123:2321-2337.
6. Banati RB (2002) Visualising microglial activation in vivo. Glia 40:206-217.
7. Boje KM, Arora PK (1992) Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 587:250-256.
8. Bolla KI, Eldreth DA, London ED, Kiehl KA, Mouratidis M, Contoreggi C, Matochik JA, Kurian V, Cadet JL, Kimes AS, Funderburk FR, Ernst M (2003) Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task. NeuroImage 19:1085-1094.
9. Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005) Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 26:480-492.
10. Buss AH, Perry M (1992) The aggression questionnaire. J Pers Soc Psychol 63:452-459.
11. Cadet JL, Jayanthi S, Deng X (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17:1775-1788.
12. Cadet JL, Jayanthi S, Deng X (2005) Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Neurotox Res 8:199-206.
13. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461-467.
14. Cagnin A, Gerhard A, Banati RB (2002) In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 12:581-586.
15. Deng X, Ladenheim B, Tsao LI, Cadet JL (1999) Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J Neurosci 19:10107-10115.
16. Deng X, Jayanthi S, Ladenheim B, Krasnova IN, Cadet JL (2002) Mice with partial deficiency of c-Jun show attenuation of methamphetamine-induced neuronal apoptosis. Mol Pharmacol 62:993-1000.
17. Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL, Peterson PK, Chao CC (1998) Cytokine regulation of human microglial cell IL-8 production. J Immunol 160:1944-1948.
18. Escubedo E, Chipana C, Pérez-Sánchez M, Camarasa J, Pubill D (2005) Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of α7 nicotinic receptors. J Pharmacol Exp Ther 315:658-667.
19. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for the diagnostic and statistical manual of mental disorders, fourth edition, patient version. Washington, D.C.: American Psychiatric.
20. Freese TE, Miotto K, Reback CJ (2002) The effects and consequences of selected club drugs. J Subst Abuse Treat 23:151-156.
21. Gruol DL, Nelson TE (1997) Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15:307-339.
22. Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Iyo M (2007) Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. Biol Psychiatry 61:577-581.
23. Jayanthi S, Deng X, Ladenheim B, McCoy MT, Cluster A, Cai NS, Cadet JL (2005) Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci USA 102:868-873.
24. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
25. Ladenheim B, Krasnova IN, Deng X, Oyler JM, Polettini A, Moran TH, Huestis MA, Cadet JL (2000) Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol 58:1247-1256.
26. 11C] raclopride studies. J Cereb Blood Flow Metab 16:42-52.
27. LaVoie MJ, Card JP, Hastings TG (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187:47-57.
28. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods R, Rawson R, Ling W (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61:73-84.
29. McCann UD, Szabo Z, Scheffel U, Dannals RF, RicaurteGA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437.
30. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM (2001) Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 169:219-230.
31. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, Colado MI (2004) 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89:1445-1453.
32. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57:168-175.
33. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, Schuckit MA (2002) Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology 26:53-63.
34. Rajkowska G, Miguel-Hidalgo JJ (2007) Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 6:219-233.
35. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214.
36. Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N (2003) Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160:1699-1701.
37. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, Okada H, Minabe Y, Suzuki K, Iwata Y, Tsuchiya KJ, Tsukada H, Iyo M, Mori N (2006) Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 63:90-100.
38. Takebayashi K, Sekine Y, Takei N, Minabe Y, Isoda H, Takeda H, Nishimura K, Nakamura K, Suzuki K, Iwata Y, Sakahara H, Mori N (2004) Metabolite alterations in basal ganglia associated with psychiatric symptoms of abstinent toluene users: a proton MRS study. Neuropsychopharmacology 29:1019-1026.
39. Thomas DM, Kuhn DM (2005a) Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 92:790-797.
40. Thomas DM, Kuhn DM (2005b) MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 1050:190-198.
41. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM (2004a) Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367:349-354.
42. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004b) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1-7.
43. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028-6036.
44. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-830.
45. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
46. Wang GJ, Volkow ND, Roque CT, Cestaro VL, Hitzemann RJ, Cantos EL, Levy AV, Dhawan AP (1993) Functional importance of ventricular enlargement and cortical atrophy in healthy subjects and alcoholics as assessed with PET, MR imaging, and neuropsychologic testing. Radiology 186:59-65.
47. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E (2005) Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 43:81-89.
48. Zhang L, Shirayama Y, Shimizu E, Iyo M, Hashimoto K (2006) Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 544:1-9.